NABUMETONE

Search structure
Trade Names:
Synonyms:
Status: Approved (1991)
Entry Type: Small molecule
Molecule Category: Parent Prodrug
ATC: M01AX01
UNII: LW0TIW155Z

Structure
InChI Key BLXXJMDCKKHMKV-UHFFFAOYSA-N
Smile COc1ccc2cc(CCC(C)=O)ccc2c1
InChI
InChI=1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3

Physicochemical Descriptors

Property Name Value
Molecular Formula C15H16O2
Molecular Weight 228.29
AlogP 3.37
Hydrogen Bond Acceptor 2.0
Hydrogen Bond Donor 0.0
Number of Rotational Bond 4.0
Polar Surface Area 26.3
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 17.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Cyclooxygenase-2 inhibitor
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Cytochrome P450 Cytochrome P450 family 1 Cytochrome P450 family 1A Cytochrome P450 1A2
- 5000 - - -
Enzyme Hydrolase
- - - -
Enzyme Oxidoreductase
- 998 - - -
Enzyme Transferase
- - - - 14.56
Epigenetic regulator Eraser Histone deacetylase HDAC class IIb
- - - - 7.27-44.67
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC06 neurotransmitter transporter family
- 1868 - 1853 -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 110.74

Metabolites

visNetwork

Indications

Mesh Heading Maximum Phase Mesh ID Reference

Related Entries

Scaffolds

Side Effects from Label

Side effects Relative Frequency (%) Labels
Gastrointestinal disorders Diarrhoea 14.0
Gastrointestinal disorders Dyspepsia 13.0
Gastrointestinal disorders Abdominal pain 12.0
Gastrointestinal disorders Gastrointestinal pain 12.0
Gastrointestinal disorders Nausea 9.0
Nervous system disorders Headache 8.0
Skin and subcutaneous tissue disorders Dermatitis 7.0
Skin and subcutaneous tissue disorders Rash 7.0
Cardiac disorders Dizziness 6.0
Gastrointestinal disorders Flatulence 6.0
Gastrointestinal disorders Constipation 4.0
Skin and subcutaneous tissue disorders Pruritus 4.0
Ear and labyrinth disorders Tinnitus 4.0
Nervous system disorders Insomnia 3.0
General disorders and administration site conditions Asthenia 2.0
Gastrointestinal disorders Dry mouth 2.0
General disorders and administration site conditions Fatigue 2.0
Investigations Occult blood positive 2.0
Nervous system disorders Somnolence 2.0
Eye disorders Visual impairment 2.0
Vascular disorders Hypertension 1.7
Cardiac disorders Dyspnoea 1.0
Gastrointestinal disorders Gastritis 1.0
General disorders and administration site conditions Hyperhidrosis 1.0
Gastrointestinal disorders Melaena 1.0
Psychiatric disorders Nervousness 1.0
Cardiac disorders Palpitations 1.0
Psychiatric disorders Tension 1.0
Gastrointestinal disorders Vomiting 1.0
Skin and subcutaneous tissue disorders Alopecia 0.9
Psychiatric disorders Depression 0.9
Ear and labyrinth disorders Vertigo 0.9
General disorders and administration site conditions Discomfort 0.8
General disorders and administration site conditions Feeling abnormal 0.8
General disorders and administration site conditions Ill-defined disorder 0.8
General disorders and administration site conditions Malaise 0.8
Nervous system disorders Paraesthesia 0.8
General disorders and administration site conditions Asthenia 0.7
General disorders and administration site conditions Decreased appetite 0.7
Renal and urinary disorders Dysuria 0.7
Gastrointestinal disorders Eructation 0.7
Gastrointestinal disorders Gastroenteritis 0.7
General disorders and administration site conditions Oedema 0.7
Immune system disorders Urticaria 0.7
Investigations Weight increased 0.7
Respiratory, thoracic and mediastinal disorders Cough 0.6
Renal and urinary disorders Albuminuria 0.5
Blood and lymphatic system disorders Anaemia 0.5
Gastrointestinal disorders Rectal haemorrhage 0.5
Psychiatric disorders Anxiety 0.4
Immune system disorders Asthma 0.4
Investigations Body temperature increased 0.4
Gastrointestinal disorders Duodenal ulcer 0.4
Gastrointestinal disorders Gastric ulcer 0.4
Renal and urinary disorders Haematuria 0.4
Blood and lymphatic system disorders Leukopenia 0.4
Gastrointestinal disorders Stomatitis 0.4
Investigations Weight decreased 0.4
Nervous system disorders Confusional state 0.3
Cardiac disorders Dizziness 0.3
Gastrointestinal disorders Dysphagia 0.3
General disorders and administration site conditions Feeling abnormal 0.3
Nervous system disorders Loss of consciousness 0.3
Vascular disorders Shock 0.3
Cardiac disorders Syncope 0.3
General disorders and administration site conditions Chills 0.2
Skin and subcutaneous tissue disorders Dermatitis bullous 0.2
Psychiatric disorders Erectile dysfunction 0.2
Gastrointestinal disorders Glossitis 0.2
Endocrine disorders Hyperglycaemia 0.2
General disorders and administration site conditions Increased appetite 0.2
Renal and urinary disorders Nephrolithiasis 0.2
Skin and subcutaneous tissue disorders Photosensitivity reaction 0.2
Blood and lymphatic system disorders Thrombocytopenia 0.2
Vascular disorders Thrombophlebitis 0.2
Cardiac disorders Acute coronary syndrome 0.1
Nervous system disorders Agitation 0.1
Blood and lymphatic system disorders Agranulocytosis 0.1
Cardiac disorders Angina pectoris 0.1
Cardiac disorders Arrhythmia 0.1
Renal and urinary disorders Azotaemia 0.1
Investigations Blood uric acid increased 0.1
Gastrointestinal disorders Duodenitis 0.1
Gastrointestinal disorders Gastrointestinal haemorrhage 0.1
Gastrointestinal disorders Gingivitis 0.1
Metabolism and nutrition disorders Hyperuricaemia 0.1
Metabolism and nutrition disorders Hypokalaemia 0.1
Cardiac disorders Myocardial infarction 0.1
Gastrointestinal disorders Pancreatitis 0.1
Nervous system disorders Tremor 0.1
Immune system disorders Vasculitis 0.1
Immune system disorders Anaphylactic shock 0.01
Immune system disorders Anaphylactoid reaction 0.01
Immune system disorders Angioedema 0.01
Psychiatric disorders Nightmare 0.01

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Skin and subcutaneous tissue disorders
17.13
Immune system disorders
16.57
Respiratory, thoracic and mediastinal disorders
9.39
General disorders and administration site conditions
8.84
Vascular disorders
8.84
Injury, poisoning and procedural complications
6.08
Gastrointestinal disorders
5.52
Nervous system disorders
5.52
Cardiac disorders
3.87
Psychiatric disorders
3.31
Metabolism and nutrition disorders
3.04
Renal and urinary disorders
3.04
Musculoskeletal and connective tissue disorders
2.49

Cross References

Resources Reference
CAS NUMBER 42924-53-8
ChEBI 7443
ChEMBL CHEMBL1070
DrugBank DB00461
DrugCentral 1863
EPA CompTox DTXSID4045472
FDA SRS LW0TIW155Z
Human Metabolome Database HMDB0014604
Guide to Pharmacology 7245
PDB NBO
PharmGKB PA450572
PubChem 4409
SureChEMBL SCHEMBL2256
ZINC ZINC000000020221
CONTENTS